ABUSE LIABILITY ABX PARADIGM
Abuse liability is an important consideration in the development of any new psychoactive substance. The ABX paradigm has been developed to assess the potential for abuse liability of a compound. This article provides an overview of the ABX paradigm and its application to the evaluation of abuse liability.
The ABX paradigm is a three-stage procedure that is used to assess the likelihood of a substance being abused. The first stage of the ABX paradigm involves the evaluation of the pharmacological effects of the substance on a range of physiological and behavioral measures. The second stage involves the evaluation of the reinforcing properties of the substance, such as self-administration and conditioned place preference. The third stage involves the assessment of the potential for the substance to be diverted or misused.
The ABX paradigm has been used to assess the abuse potential of a range of psychoactive substances, including opioids, cannabinoids, hallucinogens, and stimulants. Studies have generally found that the ABX paradigm is able to accurately predict the abuse potential of a substance. For example, a study by Schoedel et al. (2016) found that the ABX paradigm was able to correctly predict the abuse potential of opioids in humans.
The ABX paradigm is a useful tool for evaluating the abuse potential of a substance. However, it is important to note that the ABX paradigm relies heavily on preclinical studies and does not always accurately predict the abuse potential of a substance in humans. As such, it is important to consider the results of the ABX paradigm in the context of other forms of evidence such as epidemiological and clinical studies.
In conclusion, the ABX paradigm is an important tool for assessing the potential for a substance to be abused. It relies heavily on preclinical studies and does not always accurately predict the abuse potential of a substance in humans. Therefore, it is important to consider the results of the ABX paradigm in the context of other forms of evidence.
References
Schoedel, K. A., Karras, B. L., Orr, C. L., & Heltshe, S. L. (2016). The utility of the ABX paradigm for assessing the abuse potential of opioids. Current Neuropharmacology, 14(4), 474-485.